Mustang Bio, Inc. (MBIO) stock declined over -4.86% intraday to trade at $0.7023 a share on NASDAQ. The stock opened with a loss of -6.36% at $0.75 and touched an intraday high of $0.75, falling -1.78% against the last close of $0.715. The stock went to a low of $0.67 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-107 and MB-207, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-102 CAR T therapies for blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia, and myelodysplastic syndrome; MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-104 CAR T for multiple myeloma and light chain amyloidosis; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clin Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH, and Minaris Regenerative Medicine GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Mustang Bio, Inc. (NASDAQ: MBIO) stock price is $0.7023 as of the last check on Wednesday, August 17. During the trading session, MBIO stock reached the peak price of $0.75 while $0.67 was the lowest point it dropped to.
The NASDAQ listed MBIO is part of Biotechnology industry that operates in the broader Health Care sector. Mustang Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
Mr. Brian K. Achenbach M.B.A.
Sr. VP of Fin. & Corp. Controller
Ms. Debra Manning SPHR
VP of HR
Ms. Lynn E. Bayless
Head of Regulatory Affairs
Mr. Michael S. Weiss Esq.
MBIO stock traded closed the last session at $0.738, which is -$0.03589999999999993 or -4.863180709834724% lower than its previous close of $0.715. MBIO's current trading price is 44.75% lower than its 52-week high of $3.09 where as its distance from 52-week low of 0.51% is -76.11%.
Number of MBIO employees currently stands at -. MBIO operates from 377 Plantation Street, 1st floor, Worcester, MA 01605, United States.
Official Webiste of $MBIO is: https://www.mustangbio.com
MBIO stock volume for the day was 403,777 shares while in the previous session number of MBIO shares traded was 1,734,427 . The average number of MBIO shares traded daily for last 3 months was 1.03 Million.
The percentage change in MBIO stock occurred in the recent session was -4.863180709834724% while the dollar amount for the price change in MBIO stock was -$0.03589999999999993.
In the recent session, the day high for MBIO stock was $0.75 while the low for MBIO stock touched on the day was $0.67.
The market value of MBIO currently stands at 74.91 Million with its latest stock price at $0.7023 and 102.95 Million of its shares outstanding.